������Ƶ

Female survivors of childhood cancers who have been treated with thoracic radiation, such as survivors of Hodgkin’s lymphoma (HL), have a higher risk of developing breast cancer later in life compared to the general population.

To mitigate this risk, current guidelines in Ontario recommend that female HL survivors undergo annual mammography and MRI screenings starting at age 30, the same for all high-risk women.

However, Lauren Tessier and Jill Furzer (left), PhD students at the Institute of Health Policy, Management and Evaluation (IHPME), led a recent study that suggested mammographic screening in addition to MRIs for this group is a costly strategy that provides limited additional benefits in preventing cancer compared to having an MRI alone. 

“Mammograms are not as sensitive as MRI in their ability to look for new tumors, especially in women under age 50, and there is often a low compliance rate in this population of women,” said Tessier.

“Our findings show that the guidelines should be more specific to an individual’s specific risk profile and that survivors of pediatric HL would likely benefit from starting screening earlier than age 30.”

What started as a course project for Furzer and Tessier’s graduate studies in health services research at IHPME grew into a study on real-world applications that .

Furzer and Tessier conducted their study by modifying an existing breast cancer natural history model for HL survivors with a high risk of developing breast cancer. This model starts with HL survivors at age 25, who are then simulated through different screening strategies starting at either age 25 or 30 and include MRI, mammogram or both. If breast cancer is detected, the life expectancy and quality of life of these individuals and the associated health-care costs were calculated based on the frequency of screening, the timing of cancer detection and the cost of treatment.

In their findings, Furzer and Tessier found that screening with both an MRI and mammogram at age 30 is, on average, more expensive and less effective than screening using MRI only. They also found that at age 25, adding an MRI to mammography screening also added significant costs without a meaningful change in a survivor's life expectancy or quality of life.

 “Within cost-effectiveness analysis in health care, there is also a value judgement,” adds Furzer. “We are trying to determine what treatments or screening strategies provide value in terms of quality adjusted life years for these patients, while also ensuring system sustainability in terms of public funding for these services.” 

Senior author and assistant professor at IHPME Petros Pechlivanoglou notes that this kind study is important for the field of pediatric oncology as a whole. 

“In pediatric oncology there are positive effects in the short term because we prevent children from relapsing in their disease. However, it has been recognized by many that there are long-term implications that can be treatment related,” says Pechlivanoglou, who is also a scientist in child evaluative sciences at the Hospital for Sick Children. “That is why studies like this are useful in estimating the long-term effects over a lifetime for childhood cancer survivors, including costs to the health system.” 

With the study’s finding that cancer screening guidelines would benefit from some revisions, especially for HL survivors, Furzer and Tessier point out that any call for change from the status quo, especially in health care, can be tough. 

“There can be a strong emotional reaction when talking about cost in health care,” says Furzer.  Tessier agrees: “It is not our goal to only focus on costs, but to create a better health-care system and outcomes for everyone who uses it now and in the future.”